Keros Therapeutics reported a Q4 net loss of USD 23.5 million and FY net income of USD 87.0 million. Q4 revenue was USD 0.4 million, while FY total revenue was USD 244.1 million, including USD 205.4 million in license revenue and USD 38.7 million in service and other revenue. Q4 R&D expenses were USD 17.9 million and G&A expenses were USD 11.7 million; for FY, R&D expenses were USD 129.6 million and G&A expenses were USD 46.8 million. Cash and cash equivalents were USD 287.4 million at December 31, 2025, and Keros said this is expected to fund planned operating expenses and capital expenditure requirements into the first half of 2028. In business updates, Keros said it expects to start a Phase 2 trial of rinvatercept in Duchenne muscular dystrophy in Q2 2026 and plans to engage regulators on the design of a Phase 2 trial in amyotrophic lateral sclerosis in H2 2026. The company also announced board and leadership changes, including the appointment of Charles Newton to the board effective March 9, 2026, the planned departure of director Carl Gordon, and the promotion of Esther Cho to Chief Legal Officer effective February 24, 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603041601PRIMZONEFULLFEED9665243) on March 04, 2026, and is solely responsible for the information contained therein.
Comments